Cibc Private Wealth Group 13F: Cuts BMY Stake by $637K

Cibc Private Wealth Trims Bristol-Myers Squibb Holding

Cibc Private Wealth Group trimmed its stake in Bristol-Myers Squibb Company (NYSE:BMY) during the reporting period, according to a recent Form 13F filing with the Securities and Exchange Commission. The fund lowered its investment by 3.9%, selling 10,873 shares to bring its total down to 268,354 shares. At the close of the period, that remaining stake carried an estimated value of about $15.7 million.

Inside the Position Reduction

Prior to the adjustment, the fund held 279,227 shares of the drug maker. Dropping 10,873 shares amounts to a 3.9% decrease in the portfolio allocation. Institutional filings like this one reflect snapshot holdings from the end of the reporting window and may not represent the investor's current positioning today.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb shares changed hands around $58.56. The stock trades between a 52-week low of $42.52 and a 52-week high of $68.64. The company maintains a P/E ratio of 13.3 and a forward P/E ratio of 9.1. Its 50-day moving average sits at $63.59, while its 200-day moving average rests near $59.61.

Recent Earnings and Financial Health

Bristol-Myers Squibb reported revenue of $49.2 billion with a revenue growth rate of 5.7%. The drug manufacturer posted earnings of $4.54 per share alongside a net margin of 18.9% and a return on equity of 46.6%. The company's next earnings report is scheduled for October 29, 2026.

Dividend Profile

Income-focused investors note that Bristol-Myers Squibb pays an annual dividend yielding 4.2%. The company's payout ratio stands at 55.3%, meaning roughly half of its earnings go toward shareholder distributions.

Wall Street Analyst Outlook

Analyst coverage includes a mix of ratings from major financial firms. On October 13, 2026, Wells Fargo maintained an Equal-Weight rating with a $60.00 price target, lowering it from $65.00. On October 8, 2026, Cantor Fitzgerald kept a Neutral rating while cutting its target from $59.00 to $53.00. Morgan Stanley maintained an Underweight rating on October 7, 2026, raising its target slightly from $40.00 to $41.00. Leerink Partners downgraded the stock to Market Perform on October 5, 2026, dropping its target to $59.00 from $73.00. Overall, the stock carries a consensus buy recommendation with a mean target price of $65.63 across 24 analyst opinions.

About Bristol-Myers Squibb Company

Headquartered in Princeton, New Jersey, Bristol-Myers Squibb discovers and distributes biopharmaceutical treatments around the world. The company focuses on specialty drugs targeting oncology, immunology, cardiovascular diseases, and neuroscience conditions. Key portfolio treatments include Eliquis, Revlimid, Opdivo, and Pomalyst, serving hospitals, clinics, and pharmacies globally.

What to Watch at Bristol-Myers Squibb Company

Investors tracking Cibc Private Wealth Group will look to subsequent quarterly disclosures to see whether the fund continues to pare back its healthcare allocations. Because 13F filings look backward, these records serve as a historical window into past portfolio management choices rather than active buy or sell signals.